|
|
AMERICAN
BIOGENETIC SCIENCES’ TpP™ TEST STUDIES
REPORTED AT PARIS CONFERENCE
Copiague,
NY, July 19, 2001– American Biogenetic Sciences,
Inc. (ABS)(Nasdaq:MABA) announced three presentations
at the XVIII Congress of The International Society
on Thrombosis and Haemostasis in Paris, France, last
week which provided additional valuable insights into
the clinical utility of TpP, a patented test for measuring
blood levels of Thrombus Precursor Protein (TpP™).
The studies suggest a broader range of potential uses
for the company’s TpP test in excluding thrombosis
in certain patient populations.
Dr. Michael
Paidas and colleagues, Department of Ob/Gyn, New York
University School of Medicine, New York, New York,
presented data on TpP in the management of high risk
pregnancies and noted a relationship between poor
blood flow and birth weight and TpP levels.
Dr. Yale
Arkel and colleagues, Maine Medical Center Research
Institute, Portland, Maine, presented two papers evaluating
the utility of TpP in various medical conditions including
the monitoring of thrombosis in renal and oncology
patients.
These
abstracts can be viewed as follows:
http://www.cartesian-secure.com/isth2001/iAbstract/html/absP2993.html:
Markers Of The Increase In Thrombin Production In
Multiple Gestation. M.J. Paidas, Y.S. Arkel, D.H.
Ku, G. Urban, E. Kuczynski, H. Rogue, J. Maturi, S.
Kahn, J. Schoenfeld, C.J. Lockwood. Dept. of Ob/Gyn
NYU School of Medicine, NY, NY; Thrombosis research
program, Maine Medical Center Research Institute,
Portland, ME, USA
http://www.cartesian-secure.com/isth2001/iAbstract/html/absP715.html:
Comparison Of ELISA For Soluble Fibrin Polymer (TpP)
And D-Dimer In Patients With Renal Failure Or Malignancy
(Not In Remission) And Not Having Clinical Evidence
For Active Venous Thromboembolism. Y.S Arkel D.H.
Ku, P. Le, A.M. Carr. Maine Medical Center Research
Institute, S. Portland, ME USA
http://www.cartesian-secure.com/isth2001/iAbstract/html/absP3018.html:
Increased Thrombin Generation As Per Endogenous Thrombin
Potential (ETP), Coagulation Activation Markers (TpP,
TAT, And PF1.2) And TAFI Levels In Subjects Treated
With Estrogen Hormone Replacement (HRT) Y.S Arkel,
D. Spratt, D.H Ku, K. Becker T. Worster, P. Le, K.E
Domey, H. Alves, S.C. Ku, V. Ku. Maine Medical
Center Research Institute, S. Portland, Maine, USA
American
Biogenetic Sciences, Inc., based in Copiague, N.Y.,
researches and develops diagnostic tests for cardio-pulmonary
conditions and infectious diseases, as well as for
new treatments for neurological disorders including
epilepsy, migraine, mania, Parkinson’s disease
and Alzheimer’s disease.
Statements
in this press release that are not strictly historical
are “forward looking” statements within
the meaning of the Private Securities Litigation Reform
Act of 1995, and should be considered as subject to
various risks and uncertainties that could cause actual
results to differ materially from those anticipated,
including the risk that its products may not be commercialized.
For further details and a discussion of these risks
and uncertainties, see the Company's Securities and
Exchange Commission filings including its annual report
on Form 10K.
For a complete analysis of the ABS pipeline go
to:
/research.html
|
 |
